SAN DIEGO, CA--(Marketwire - February 25, 2011) - Cytori Therapeutics (
This '952 patent is the Company's first to issue in Japan, creating a significant barrier-to-entry through at least 2022 in the second largest medical market in the world and a country where Cytori has ongoing strategic and commercial activities. Cytori formed a Joint Venture with Olympus Corporation in 2005 to develop and manufacture future generation devices based on Cytori's Celution® System.
With claims similar to the core 7,390,484 patent in the United States, this patent will serve as the foundational patent in Japan, around which Cytori has applied for additional patents covering specific applications for the cells.
Cytori now has 30 issued patents worldwide, including 11 issued patents in the United States as well as issued patents in Korea, China, Singapore and more than 100 additional pending applications worldwide. Our existing patents cover the Company's core device technology which automates the process of extracting a mixed population of adipose-derived stem and regenerative cells by way of a closed, bedside system, as well as methods and uses of these cells for a variety of clinical applications.
About Cytori
Cytori is a leader in providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution® System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource® product line is sold globally for cell banking and research applications. www.cytori.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, such as the statement that the '952 patent would serve as a significant barrier to entry in Japan, which could affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, inherent risk and uncertainty in the protection of intellectual property rights, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, including its annual report on Form 10-K for the year ended December 31, 2009. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.
Contact Information:
Contact:
U.S. Investors/Media
Tom Baker
tbaker@cytori.com
+1.858.232.7234
Japan
Megumi Okabe
mokabe@cytori.com
+81.3.5319.8371